MMP9 Antibody - #AF0220

(8)   (6)  
製品: MMP9 Antibody
カタログ: AF0220
タンパク質の説明: Rabbit polyclonal antibody to MMP9
アプリケーション: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
反応性: Human, Mouse
分子量: 78kDa; 78kD(Calculated).
ユニプロット: P14780
RRID: AB_2833350

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse
クローナリティ:
Polyclonal
特異性:
MMP9 Antibody detects endogenous levels of total MMP9.
RRID:
AB_2833350
引用形式: Affinity Biosciences Cat# AF0220, RRID:AB_2833350.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

82 kDa matrix metalloproteinase-9; 92 kDa gelatinase; 92 kDa type IV collagenase; CLG 4B; CLG4B; Collagenase Type 4 beta; Collagenase type IV 92 KD; EC 3.4.24.35; Gelatinase 92 KD; Gelatinase B; Gelatinase beta; GelatinaseB; GELB; Macrophage gelatinase; MANDP2; Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); Matrix Metalloproteinase 9; MMP 9; MMP-9; MMP9; MMP9_HUMAN; Type V collagenase;

免疫原

免疫原:

A synthesized peptide derived from human MMP9, corresponding to a region within C-terminal amino acids.

Uniprot:

P14780(MMP9_HUMAN) >>Visit HPA database.

遺伝子(ID):
MMP9(4318)
発現特異性:
P14780 MMP9_HUMAN:

Detected in neutrophils (at protein level) (PubMed:7683678). Produced by normal alveolar macrophages and granulocytes.

タンパク質の説明:
MMP9 May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. Belongs to the peptidase M10A family. Activated by 4-aminophenylmercuric acetate and phorbol ester. Exists as monomer or homodimer; disulfide-linked. Exists also as heterodimer with a 25 kDa protein. Macrophages and transformed cell lines produce only the monomeric form. Interacts with ECM1.
タンパク質配列:
MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTQDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEERLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED

研究背景

機能:

May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.

PTMs:

Processing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9.

N- and O-glycosylated.

細胞の位置付け:

Secreted>Extracellular space>Extracellular matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Detected in neutrophils (at protein level). Produced by normal alveolar macrophages and granulocytes.

タンパク質ファミリー:

The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Belongs to the peptidase M10A family.

研究領域

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

参考文献

1). The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. CANCER LETTERS, 2019 (PubMed: 30954648) [IF=9.1]
2). Precise Control of the in vivo Fate of Nanomicelles Efficiently Treats Advanced Rheumatoid Arthritis via EGFR/JNK/MMP9 Pathway. International journal of nanomedicine, 2025 (PubMed: 40303575) [IF=6.6]

Application: IF/ICC    Species: Mouse    Sample: RAW264.7 cells

Figure 9 The effects of SWE-NMs on expression of EGFR (A and B), JNK (C and D) and MMP9 (E and F). Immunofluorescence staining of EGFR (red), JNK (red), MMP9 (green) and nuclei (blue) on RAW264.7 cells in different groups. Scale bar=20 μm. The statistical graphs of the expression of EGFR, JNK and MMP9 based on semi-quantitative analysis of the in vitro fluorescence images after i.v. administration of SWE-NMs in RAW264.7 cells. Statistical significance was determined by two-sided Student’s t-test. Data represent mean ± SD. # P < 0.05 vs Normal group; * P
3). A novel benzothiazole derivative induces apoptosis via the mitochondrial intrinsic pathway producing antitumor activity in colorectal cancer. Frontiers in Pharmacology, 2023 (PubMed: 37288115) [IF=5.6]

Application: WB    Species: Mouse    Sample:

FIGURE 5 BTD inhibited the migration and invasion ability of cells. (A,B) Cells were treated with BTD (0, 2.5, 5, or 10 μM) for 24 h and subjected to migration (A) and invasion (B) assays, and then photographed (×100). (C) Cells were seeded, and a “wound” was created, then incubated with BTD (0, 2.5, 5, or 10 μM) for 24 h and photographed (×100). The lines indicate the area occupied by the initial scraping, and migrated cells were quantified. (D) The levels of MMP2, MMP9, and TIMP2 were detected using Western blotting. (E,F) Flow cytometry was used to analyze the cell cycle distribution. The values are shown as histograms.
4). A novel long non-coding RNA LINC00355 promotes proliferation of lung adenocarcinoma cells by down-regulating miR-195 and up-regulating the expression of CCNE1. CELLULAR SIGNALLING, 2020 (PubMed: 31689506) [IF=4.4]
5). Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway. Oncology Reports, 2019 (PubMed: 30864730) [IF=3.8]

Application: WB    Species: human    Sample: HepG2TMOD3, Hep3BshTMOD3 and their control cells.

Figure 4. |TMOD3 is associated with EMT and activates the MAPK/ERK signaling pathway.N=140 (D) The expression of critical members and downstream effectors of the MAPK/ERK signaling pathway was examined by western blot analysis in HepG2TMOD3, Hep3BshTMOD3 and their control cells. TMOD3, tropomodulin 3; EMT, epithelial‑to‑mesenchymal transition; ES, enrichment score; NES, normalized enrichment score; MAPK, mitogen‑activated protein kinase; MMP, matrix metalloproteinase; ERK, extracellular signal‑regulated kinase; shRNA, short hairpin RNA; KRAS, Kirsten rat sarcoma viral proto‑oncogene; HCC, hepatocellular carcinoma.
6). TEAD4 predicts poor prognosis and transcriptionally targets PLAGL2 in serous ovarian cancer. Human cell, 2023 (PubMed: 37145265) [IF=3.4]
7). Compared with High-intensity Interval Exercise, Moderate Intensity Constant Load Exercise is more effective in curbing the Growth and Metastasis of Lung Cancer. Journal of Cancer, 2022 (PubMed: 35371324) [IF=3.3]

Application: WB    Species: mouse    Sample: lung cancer

Figure 5.| The effect of exercise on EMT and its inducing factors in lung cancer tissues. D, E. The expression level of vimentin in lung cancer tissues (n=6). D, F, G. The expression levels of MMP2 (D, F) and MMP9 (D, G) in lung cancer tissues (n=6). D, H. The expression level of TGF-β1 in lung cancer tissues (n=6). D, I. The expression level of collagen type I in lung cancer tissues(n=6). Note: &, &&&& respectively represent a significant difference compared with the Saline group (P<0.05), (P<0.0001).
8). Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget, 2016 (PubMed: 26933912)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.